Lilly's lupus loss is XTL's gain; AstraZeneca and Clovis race to the lung cancer market;

@FierceBiotech: IPO hopeful rEVO puts off its plans for a $75M debut. Item | Follow @FierceBiotech

@JohnCFierce: Interesting to see which #biotech #IPOs do well and which flop. Congrats to $DERM. | Follow @JohnCFierce

@DamianFierce: ICYMI: $LLY's bailing on tabalumab­ in lupus after two Phase III misses. Release | Follow @DamianFierce

@EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. | Follow @EmilyMFierce

> Eli Lilly's ($LLY) announcement that its late-stage tabalumab failed in lupus, boosted shares of XTL Biopharmaceuticals ($XTLB), at work on its own treatment for the disease. News

> AstraZeneca ($AZN) and Clovis Oncology ($CLVS) are racing to the FDA with drugs for treatment-resistant lung cancer, angling for position in a market expected to clock in at $3 billion a year. Story

Medical Device News

@FierceMedDev: Have you checked out our 15 most promising #medtech companies yet? Report | Follow @FierceMedDev

@VarunSaxena2: Alnylam says it wants to enter larger disease areas using partnership-driven approach. News | Follow @VarunSaxena2

@EmilyWFierce: FDA cracking down on companies marketing essential oils as treatments or cures for Ebola. More from the WSJ | Follow @EmilyWFierce

> Hopkins physician creates 3-D printed hands for pediatric patients. More

> EU regulators to conduct antitrust probe of $13.4B Zimmer/Biomet deal. Story

> Glooko enables wireless smartphone access for existing blood glucose monitors. News

Pharma News

@FiercePharma: Did you miss our latest special report yesterday? Not to worry: Top 10 pharma companies by employees - 2014. Report | Follow @FiercePharma

@CarlyHFierce: Salix drops Cosmo buy, opting to talk takeover with Actavis. More | Follow @CarlyHFierce

> Ascension hospitals bar Genentech reps after cancer drug distribution switch. Story

> NICE nixes Roche's new leukemia drug Gazyvaro despite discount offer. News

> Add Arbor Pharma to your shopping list: It's on the block for $1B-plus. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.